Data calculated per time period
| Parameter | Period 1 | Period 2 | Period 3 |
| Total no of patients | 882 | 814 | 2434 |
| Patient characteristics | |||
| No of male patients | |||
| Patients included | 882 | 814 | 2434 |
| Male patients (%) | 495 (56.1) | 427 (52.5) | 1195 (49.1) |
| Age (years) | |||
| Patients included | 617 | 814 | 1507 |
| Mean±SD | 47.64±11.67 | 47.25±11.09 | 49.18±11.78 |
| No of Caucasian patients | |||
| Patients included | 578 | 814 | 1506 |
| Caucasian patients (%) | 537 (92.9) | 793 (97.4) | 1306 (86.7) |
| Weight (kg) | |||
| Patients included | 312 | 408 | 1507 |
| Mean±SD | 85.74±18.60 | 84.41±18.78 | 85.91±20.44 |
| Disease characteristics | |||
| Duration of PsA (years) | |||
| Patients included | 617 | 814 | 504 |
| Mean±SD | 9.30±8.20 | 8.02±7.90 | 7.53±7.40 |
| No of patients with dactylitis | |||
| Patients included | 304 | 814 | 2434 |
| Patients with dactylitis (%) | 132 (43.4) | 245 (30.1) | 1081 (44.4) |
| No of patients with enthesitis | |||
| Patients included | 304 | 814 | 2434 |
| Patients with enthesitis (%) | 103 (33.9) | 546 (67.1) | 1602 (65.8) |
| No of patients with BSA ≥3% | |||
| Patients included | 573 | 814 | 2434 |
| Patients with BSA ≥3% (%) | 348 (60.7) | 548 (67.3) | 1424 (58.5) |
| Disease activity | |||
| SJC | |||
| Patients included | 617 | 814 | 1507 |
| Mean±SD | 14.31±10.10 | 11.89±9.00 | 12.65±10.00 |
| TJC | |||
| Patients included | 617 | 814 | 1507 |
| Mean±SD | 24.39±15.70 | 21.6±15.50 | 23.26±16.60 |
| CRP level (mg/L) | |||
| Patients included | 617 | 405 | 504 |
| Mean±SD | 18.36±25.00 | 13.36±16.70 | 9.47±13.00 |
| Physician's global assessment of disease activity (VAS 0–10 cm) | |||
| Patients included | 614 | 409 | 1507 |
| Mean±SD | 5.49±1.70 | 5.79±1.90 | 5.59±1.90 |
| Patient's global assessment of disease activity (VAS 0–10 cm) | |||
| Patients included | 616 | 409 | 1507 |
| Mean±SD | 5.16±2.20 | 5.91±2.10 | 5.71±2.20 |
| Patient's global assessment of pain (VAS 0–10 cm) | |||
| Patients included | 616 | 409 | 1507 |
| Mean±SD | 5.32±2.20 | 6.03±2.00 | 5.67±2.20 |
| DAS (0–10) | |||
| Patients included | 104 | 405 | 1507 |
| Mean±SD | 5.45±1.10 | 4.34±1.00 | 4.84±1.10 |
| PASI (0–72 scale) | |||
| Patients included | 308 | 296 | 744 |
| Mean±SD | 9.47±9.30 | 9.90±8.60 | 12.04±10.80 |
| Disease effects | |||
| TSS (0–528) | |||
| Patients included | 311 | 409 | 606 |
| Mean±SD | 20.84±40.90 | 21.70±43.00 | 23.33±50.70 |
| HAQ-DI score (0–3) | |||
| Patients included | 617 | 409 | 1507 |
| Mean±SD | 1.06±0.70 | 1.30±0.70 | 1.22±0.70 |
| Prior treatments | |||
| No of patients with prior anti-TNF therapy | |||
| Patients included | No data | 409 | 1507 |
| Patients with prior anti-TNF therapy (%) | 80 (19.6) | 436 (28.9) | |
| No of patients with baseline use of MTX | |||
| Patients included | 778 | 814 | 2434 |
| Patients with baseline use of MTX (%) | 363 (46.7) | 454 (55.8) | 1278 (52.5) |
| No of patients with baseline use of oral CS | |||
| Patients included | 465 | 405 | 2434 |
| Patients with baseline use of oral CS (%) | 78 (16.8) | 65 (16) | 375 (15.4) |
| No of patients with baseline use of NSAIDs | |||
| Patients included | 465 | 405 | 1431 |
| Patients with baseline use of NSAIDs (%) | 362 (77.9) | 308 (76) | 1037 (72.5) |
The number of patients considered for each parameter is mentioned under ‘patients included’. For the continuous data, we calculated a weighted mean and SD per period. For the discrete data, we summed up the patients meeting the criterium from all the studies in a given period and calculated a percentage per that specified period.
BSA, body surface area; CRP, C reactive protein; CS, corticosteroid; DAS, Disease Activity Score; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PASI, Psoriasis Area Severity Index; PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor; TSS, Total Sharp Score; VAS, Visual Analogue Scale.